TAS-303

TAS-303 is a highly selective noradrenaline (norepinephrine) reuptake inhibitor developed by Taiho Pharmaceutical for the treatment of stress urinary incontinence (SUI), particularly in women. Unlike duloxetine, which also inhibits serotonin reuptake and can cause central nervous system side effects, TAS-303 acts peripherally and does not significantly affect serotonin levels, minimizing CNS-related adverse events. Its mechanism increases urethral sphincter contractility by elevating norepinephrine concentrations at peripheral adrenergic synapses, thereby enhancing basal urethral pressure and leak point pressure. Clinical trials have shown that once-daily oral administration of TAS-303 provides superior efficacy to placebo in reducing SUI episode frequency with an adequate safety profile[1][2][6][8].